Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Semin Radiat Oncol. 2015 Feb 21;25(3):172–180. doi: 10.1016/j.semradonc.2015.02.003

Table 1.

Updated Response Assessment Criteria for Low Grade Glioma: Response Assessment in Neuro-Oncology Working Group (RANO)

Response Criteria
Complete Response Requires all of the following compared with baseline scan:

  1. complete disappearance of the lesion on T2/FLAIRimaging (if enhancement had been present, it must have resolved completely)

  2. no new lesions; no new T2/FLAIR abnormalities apart from those consistent with radiation effects, and no new or increased enhancement

  3. patients must be off corticosteroids (or on physiologic replacement doses only)

  4. patient is stable or improved clinically
Partial Response Requires all of the following compared with baseline scan:

  1. ≥50%decrease in the product of perpendicular diameters of the lesion onT2/FLAIR imaging for ≥4 weeks

  2. no new lesions, no new T2/FLAIR abnormalities apart from those consistent with radiation effects, and no new or increased enhancement

  3. same or lower dose of corticosteroids compared with dose at baseline scan

  4. patient is stable or improved clinically
Minor Response Requires all of the following compared with baseline scan:

  1. decrease in area of nonenhancing lesion on T2/FLAIR between 25–50%

  2. no new lesions, no new T2/FLAIR abnormalities apart from those consistent with radiation effect, and no new or increased enhancement

  3. same or lower dose of corticosteroids compared with dose at baseline scan

  4. patient is stable or improved clinically
Stable Disease Requires all of the following:

  1. does not qualify for complete response, partial response, minor response or progression

  2. stable area of nonenhancing abnormalities on T2/FLAIR

  3. no new lesions, no new T2/FLAIR abnormalities apart from those consistent with radiation effect, and no new or increased enhancement

  4. same or lower dose of corticosteroids compared with dose at baseline scan

  5. patient is stable or improved clinically
Progression Any of the following:

  1. any new lesion or increase of enhancement (radiological evidence of malignant transformation);

  2. ≥25% increase of T2/FLAIR nonenhancing lesion on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not attributable to radiation effect or to comorbid events

  3. clear clinical deterioration not attributable to other causes apart from tumor or changes in corticosteroid dose

  4. failure to return for evaluation as a result of death or deteriorating condition, unless caused by documented non-related disorders